153 related articles for article (PubMed ID: 9395153)
1. Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy.
de Haan E; van Oppen P; van Balkom AJ; Spinhoven P; Hoogduin KA; Van Dyck R
Acta Psychiatr Scand; 1997 Nov; 96(5):354-61. PubMed ID: 9395153
[TBL] [Abstract][Full Text] [Related]
2. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up.
van Oppen P; van Balkom AJ; de Haan E; van Dyck R
J Clin Psychiatry; 2005 Nov; 66(11):1415-22. PubMed ID: 16420079
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J
J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.
Hembree EA; Riggs DS; Kozak MJ; Franklin ME; Foa EB
CNS Spectr; 2003 May; 8(5):363-71, 381. PubMed ID: 12766692
[TBL] [Abstract][Full Text] [Related]
5. Cognitive therapy versus fluvoxamine as a second-step treatment in obsessive-compulsive disorder nonresponsive to first-step behavior therapy.
van Balkom AJ; Emmelkamp PM; Eikelenboom M; Hoogendoorn AW; Smit JH; van Oppen P
Psychother Psychosom; 2012; 81(6):366-74. PubMed ID: 22964609
[TBL] [Abstract][Full Text] [Related]
6. Sudden gains in the treatment of obsessive-compulsive disorder.
Aderka IM; Anholt GE; van Balkom AJ; Smit JH; Hermesh H; van Oppen P
Psychother Psychosom; 2012; 81(1):44-51. PubMed ID: 22116471
[TBL] [Abstract][Full Text] [Related]
7. Outcome of additional behaviour therapy including treatment discontinuation for fluvoxamine non-responders with obsessive-compulsive disorder.
Nakatani E; Nakagawa A
Psychother Psychosom; 2008; 77(6):393-4. PubMed ID: 18716426
[No Abstract] [Full Text] [Related]
8. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome for adolescent obsessive-compulsive disorder in a specialized hospital setting.
Björgvinsson T; Wetterneck CT; Powell DM; Chasson GS; Webb SA; Hart J; Heffelfinger S; Azzouz R; Entricht TL; Davidson JE; Stanley MA
J Psychiatr Pract; 2008 May; 14(3):137-45. PubMed ID: 18520782
[TBL] [Abstract][Full Text] [Related]
10. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder.
van Balkom AJ; de Haan E; van Oppen P; Spinhoven P; Hoogduin KA; van Dyck R
J Nerv Ment Dis; 1998 Aug; 186(8):492-9. PubMed ID: 9717867
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine.
Nakatani E; Nakagawa A; Nakao T; Yoshizato C; Nabeyama M; Kudo A; Isomura K; Kato N; Yoshioka K; Kawamoto M
Psychother Psychosom; 2005; 74(5):269-76. PubMed ID: 16088264
[TBL] [Abstract][Full Text] [Related]
12. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
Simpson HB; Gorfinkle KS; Liebowitz MR
J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
[TBL] [Abstract][Full Text] [Related]
13. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
[TBL] [Abstract][Full Text] [Related]
14. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.
Rufer M; Hand I; Alsleben H; Braatz A; Ortmann J; Katenkamp B; Fricke S; Peter H
Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):121-8. PubMed ID: 15812606
[TBL] [Abstract][Full Text] [Related]
15. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study.
Hohagen F; Winkelmann G; Rasche-Rüchle H; Hand I; König A; Münchau N; Hiss H; Geiger-Kabisch C; Käppler C; Schramm P; Rey E; Aldenhoff J; Berger M
Br J Psychiatry Suppl; 1998; (35):71-8. PubMed ID: 9829029
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome in adults with obsessive-compulsive disorder.
Bloch MH; Green C; Kichuk SA; Dombrowski PA; Wasylink S; Billingslea E; Landeros-Weisenberger A; Kelmendi B; Goodman WK; Leckman JF; Coric V; Pittenger C
Depress Anxiety; 2013 Aug; 30(8):716-22. PubMed ID: 23532944
[TBL] [Abstract][Full Text] [Related]
17. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
18. Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study.
Anand N; Sudhir PM; Math SB; Thennarasu K; Janardhan Reddy YC
J Anxiety Disord; 2011 Oct; 25(7):939-45. PubMed ID: 21689902
[TBL] [Abstract][Full Text] [Related]
19. Issues in the pharmacological treatment of obsessive-compulsive disorder.
Math SB; Janardhan Reddy YC
Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
[TBL] [Abstract][Full Text] [Related]
20. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
